Catalyst Pharmaceuticals
Pharmaceuticals, 355 Alhambra Cir Ste 1250, Coral Gables, Florida, 33134, United States, 51-200 Employees
Phone Number: +18*********
Who is CATALYST PHARMACEUTICALS
About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...
Read More
-
Headquarters: 355 Alhambra Cir Ste 1250, Coral Gables, Florida, 33134, United States
-
Date Founded: 2002
-
Employees: 51-200
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
-
CEO:
Isabel Nunez
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from CATALYST PHARMACEUTICALS
Catalyst Pharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Catalyst Pharmaceuticals
Answer: Catalyst Pharmaceuticals's headquarters are located at 355 Alhambra Cir Ste 1250, Coral Gables, Florida, 33134, United States
Answer: Catalyst Pharmaceuticals's phone number is +18*********
Answer: Catalyst Pharmaceuticals's official website is https://catalystpharma.com
Answer: Catalyst Pharmaceuticals's revenue is $100 Million to $250 Million
Answer: Catalyst Pharmaceuticals's SIC: 2834
Answer: Catalyst Pharmaceuticals's NAICS: 325412
Answer: Catalyst Pharmaceuticals has 51-200 employees
Answer: Catalyst Pharmaceuticals is in Pharmaceuticals
Answer: Catalyst Pharmaceuticals contact info: Phone number: +18********* Website: https://catalystpharma.com
Answer: About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
CEO at Catalyst Pharmaceuticals
Sign in to CIENCE GO Data to uncover contact details
Free credits every month